Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high21.000 03/01/17
52 week low12.000 28/06/17
52 week change -5.250 (-30.43%)
4 week volume2,726,961 02/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix widens FY pretax loss, revenue up

Tissue Regenix has reported a year of significant progress as it lifted revenue, but saw its pre-tax loss for the period widen. ...

Annual results for period ended 31 December 2016

Announcement of full year/4th quarter financial results

Tissue Regenix updates on potential acquisition of CellRight

Tissue Regenix Group said it has noted the recent dissolution of the temporary restraining order ("TRO") issued by Bexar ...

Potential Acquisition Update

Statement regarding an acquisition of a company or assets

Tissue Regenix looks to acquire CellRight

Tissue Regenix Group said it has noted the recent application for a temporary restraining order filed by one of the membe...

Potential Acquisition

Statement regarding an acquisition of a company or assets

Tissue Regenix issues equity

Tissue Regenix Group has today issued and allotted about 1.3m shares of 0.5p each, following an exercise of options which w...

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

hardman & co
Tissue Regenix Group Plc
17/03/2017
TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have...
edison investment research
Tissue Regenix Group Plc
03/02/2017
Edison Investment Research is terminating coverage on Tissue Regenix Group (TRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...
edison investment research
Tissue Regenix Group Plc
19/10/2016
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound...

Latest discussion posts More

  • Re: ouch!

    Basically we've got a sound company still suffering from growing pains. The product is good the pipeline is good. Future revenues should skyrocket if the overpaid sales force ...
    19-Jun-2017
    theprior
  • Re: ouch!

    NB I indicated a weak sell because I sold on March 22nd at 15.1p, not liking the look of the share price movement at that time and being of the opinion that TRX "just may be" a ...
    19-Jun-2017
    Loldemort
  • Re: ouch!

    Loss increased and contemplating buying another company. Both these things tend to be negative for the share price in the short term. In the long term, the purchase, if it ...
    19-Jun-2017
    Loldemort

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.31%
BP24%
TESCO18%
AVIVA17%
SIRIUS MINERALS17%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX